<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430482</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA017904</org_study_id>
    <secondary_id>R01DA017904</secondary_id>
    <nct_id>NCT00430482</nct_id>
  </id_info>
  <brief_title>Stress, Distress Intolerance, and Drug Dependence</brief_title>
  <official_title>Stress, Distress Intolerance, and Drug Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University Charles River Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University Charles River Campus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the relative efficacy of a novel treatment (CBT-IC) versus
      a standard individual drug-counseling treatment. The novel treatment emphasizes exposure to
      emotional cues for drug use as part of a comprehensive, yet brief, treatment strategy. These
      treatments are delivered to opiate-dependent, often poly-substance dependent, individuals in
      a comprehensive methadone maintenance program who have failed to respond adequately to
      current treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study study is designed to test further the efficacy of Cognitive-Behavior Therapy for
      Interoceptive Cues (CBT-IC - a treatment with a central focus on enhancing a patient's
      tolerance to the myriad forms of distress—sadness, boredom, anxiety, withdrawal sensations,
      etc.—that are linked to the stressful lives of drug-dependent individuals, and breaking the
      link between these emotional cues and drug-related attempts to avoid emotional distress) for
      intervening with chronically-stressed and treatment-resistant opiate-dependent outpatients.
      Features of this study of particular relevance to to RFA DA-04-001 include: (1) a focus on
      opiate-dependent patients undergoing chronic stress; (2) a model for the way in which chronic
      stress translates into chronic drug use; (2) a focus on the way in which stress-related
      symptoms serve as trigger for drug use; (3) a focus on both mediators and moderators of
      treatment that will inform treatment-matching efforts, including a focus on gender
      differences and emotional avoidance/distress intolerance; and (4) the examination of
      treatment outcome in a Stage II treatment trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Positive Toxicology Swabs for Illicit Substances</measure>
    <time_frame>Weekly assessments with summation over three time periods: baseline, treatment, and eight weeks of follow-up.</time_frame>
    <description>The primary outcome assessment for this study was the percentage of oral toxicology swabs that were positive of illicit substances. Participants completed these swabs at each assessment point, as well as at each study therapy session. Toxicology swabs were supervised by study staff and used oral specimen collection to screen for opiates, methadone, cocaine, benzodiazepines, amphetamines, THC, and barbiturates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Addiction Severity Index (ASI) Drug Composite Index</measure>
    <time_frame>Baseline, Mid Treatment, Treatment Endpoint, Follow-up Evaluation 1, Follow-up Evaluation 2</time_frame>
    <description>The composite score for drug use is determined by answers to 13 questions on the ASI: A/390 + B/390 + C/390 + D/390 + E/390 + F/390 + G/390 +H/390 + I/390 + J/390 + K/390 + L/52 + M/52. A single score is provided, with possible scores ranging from 0 to 1, with higher scores indicate greater drug use.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Substance Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitive Behavioral Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individual Counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>12 weekly sessions and 3 booster sessions of cognitive behavioral therapy</description>
    <arm_group_label>1</arm_group_label>
    <other_name>CBT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Individual Counseling</intervention_name>
    <description>12 weekly sessions and 3 booster sessions of individual counseling</description>
    <arm_group_label>2</arm_group_label>
    <other_name>ICT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The primary selection criteria include women and men between the ages of 18 and 65
             who:

               1. Meet DSM-IV criteria for opiate dependence,

               2. Maintain a stable dose of methadone for two weeks prior to recruitment and,

               3. a) fail to achieve &quot;take-home&quot; status for methadone dosing during at least the
                  first four months of methadone treatment, b) test positive on at least two
                  toxicology screens for illicit drugs during the month prior to recruitment c)
                  have never achieved two consecutive toxicology screens free of illicit substances
                  since entering the current treatment episode.

               4. Meet study criteria for chronic stress

                    1. unemployment criteria, and

                    2. affective disorder criteria.

        Exclusion Criteria:

          -  (1) Patients with significantly unstable or uncontrolled medical illness which may
             interfere with participation in treatment (e.g., patients likely to require
             hospitalization during the study period).

             (2) Patients with a psychotic or organic mental disorder according to DSM-IV criteria.

             (3) Patients receiving medication affecting methadone metabolism (e.g. rifampin).

             (4) Patients with uncontrolled bipolar disorder as evidenced by meeting current
             criteria for mania or hypomania or meeting criteria for rapid cycling in the last year
             (as indicated by structured questioning of all patients meeting criteria for bipolar
             disorder).

             (5) Patients unable to complete the informed consent or unable to understand study
             procedures in the informed consent process.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W. Otto, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark H. Pollack, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven A. Safren, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bay Cove Treatment Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Habit Management Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hearon BA, Calkins AW, Halperin DM, McHugh RK, Murray HW, Otto MW. Anxiety sensitivity and illicit sedative use among opiate-dependent women and men. Am J Drug Alcohol Abuse. 2011 Jan;37(1):43-7. doi: 10.3109/00952990.2010.535581. Epub 2010 Nov 19. Erratum in: Am J Drug Alcohol Abuse. 2011 Jan;37(1):47.</citation>
    <PMID>21090958</PMID>
  </reference>
  <results_reference>
    <citation>McHugh RK, Murray HW, Hearon BA, Pratt EM, Pollack MH, Safren SA, Otto MW. Predictors of dropout from psychosocial treatment in opioid-dependent outpatients. Am J Addict. 2013 Jan;22(1):18-22. doi: 10.1111/j.1521-0391.2013.00317.x.</citation>
    <PMID>23398222</PMID>
  </results_reference>
  <results_reference>
    <citation>McHugh RK, Weitzman M, Safren SA, Murray HW, Pollack MH, Otto MW. Sexual HIV risk behaviors in a treatment-refractory opioid-dependent sample. J Psychoactive Drugs. 2012 Jul-Aug;44(3):237-42.</citation>
    <PMID>23061323</PMID>
  </results_reference>
  <results_reference>
    <citation>Otto MW, Hearon BA, McHugh RK, Calkins AW, Pratt E, Murray HW, Safren SA, Pollack MH. A randomized, controlled trial of the efficacy of an interoceptive exposure-based CBT for treatment-refractory outpatients with opioid dependence. J Psychoactive Drugs. 2014 Nov-Dec;46(5):402-11. doi: 10.1080/02791072.2014.960110.</citation>
    <PMID>25364993</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 31, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <results_first_submitted>May 3, 2017</results_first_submitted>
  <results_first_submitted_qc>July 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2019</results_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University</investigator_affiliation>
    <investigator_full_name>Michael Otto</investigator_full_name>
    <investigator_title>Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Substance Dependence</keyword>
  <keyword>Cognitive-Behavior Therapy</keyword>
  <keyword>Opiate Dependence</keyword>
  <keyword>Treatment Moderators</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited via study flyers and postings or were referred to study staff by their substance abuse counselor.</recruitment_details>
      <pre_assignment_details>133 individuals were consented. Eleven dropped out prior to SCID administration. At the intake visit, 27 individuals were deemed ineligible. Of the 95 individuals who were eligible, 17 dropped out prior to randomization (7 were discharged, 2 declined treatment, and 8 were lost to contact). A total of 78 individuals were randomized to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive Behavioral Therapy
Cognitive Behavioral Therapy: 12 weekly sessions and 3 booster sessions of cognitive behavioral therapy</description>
        </group>
        <group group_id="P2">
          <title>Individual Drug Counseling</title>
          <description>Individual Drug Counseling
Individual Counseling: 12 weekly sessions and 3 booster sessions of individual counseling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Completed Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed ASI at Midpoint</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insufficient Treatment</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Completed 2 Follow-Up Visits</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed ASI at Follow-Up #1</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed ASI at Follow-Up #2</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized sample</population>
      <group_list>
        <group group_id="B1">
          <title>Cognitive Behavior Therapy</title>
          <description>Psychosocial treatment with an individualized therapy emphasizing interoceptive exposure and training alternative responses to cues for drug use</description>
        </group>
        <group group_id="B2">
          <title>Individual Drug Counseling</title>
          <description>Psychosocial treatment with individual drug counseling</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="9.8"/>
                    <measurement group_id="B2" value="42.4" spread="10.0"/>
                    <measurement group_id="B3" value="42.3" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Positive Toxicology Swabs for Illicit Substances</title>
        <description>The primary outcome assessment for this study was the percentage of oral toxicology swabs that were positive of illicit substances. Participants completed these swabs at each assessment point, as well as at each study therapy session. Toxicology swabs were supervised by study staff and used oral specimen collection to screen for opiates, methadone, cocaine, benzodiazepines, amphetamines, THC, and barbiturates.</description>
        <time_frame>Weekly assessments with summation over three time periods: baseline, treatment, and eight weeks of follow-up.</time_frame>
        <population>Randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy
Cognitive Behavioral Therapy: 12 weekly sessions and 3 booster sessions of cognitive behavioral therapy</description>
          </group>
          <group group_id="O2">
            <title>Individual Drug Counseling</title>
            <description>Individual Drug Counseling
Individual Counseling: 12 weekly sessions and 3 booster sessions of individual counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Positive Toxicology Swabs for Illicit Substances</title>
          <description>The primary outcome assessment for this study was the percentage of oral toxicology swabs that were positive of illicit substances. Participants completed these swabs at each assessment point, as well as at each study therapy session. Toxicology swabs were supervised by study staff and used oral specimen collection to screen for opiates, methadone, cocaine, benzodiazepines, amphetamines, THC, and barbiturates.</description>
          <population>Randomized participants</population>
          <units>percentage of positive toxicology screen</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" spread="24.3"/>
                    <measurement group_id="O2" value="79.1" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" spread="18.7"/>
                    <measurement group_id="O2" value="82.3" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up Period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" spread="27.4"/>
                    <measurement group_id="O2" value="74.8" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Addiction Severity Index (ASI) Drug Composite Index</title>
        <description>The composite score for drug use is determined by answers to 13 questions on the ASI: A/390 + B/390 + C/390 + D/390 + E/390 + F/390 + G/390 +H/390 + I/390 + J/390 + K/390 + L/52 + M/52. A single score is provided, with possible scores ranging from 0 to 1, with higher scores indicate greater drug use.</description>
        <time_frame>Baseline, Mid Treatment, Treatment Endpoint, Follow-up Evaluation 1, Follow-up Evaluation 2</time_frame>
        <population>Randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy
Cognitive Behavioral Therapy: 12 weekly sessions and 3 booster sessions of cognitive behavioral therapy</description>
          </group>
          <group group_id="O2">
            <title>Individual Drug Counseling</title>
            <description>Individual Drug Counseling
Individual Counseling: 12 weekly sessions and 3 booster sessions of individual counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Addiction Severity Index (ASI) Drug Composite Index</title>
          <description>The composite score for drug use is determined by answers to 13 questions on the ASI: A/390 + B/390 + C/390 + D/390 + E/390 + F/390 + G/390 +H/390 + I/390 + J/390 + K/390 + L/52 + M/52. A single score is provided, with possible scores ranging from 0 to 1, with higher scores indicate greater drug use.</description>
          <population>Randomized participants</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".23" spread=".09"/>
                    <measurement group_id="O2" value=".21" spread=".12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".20" spread=".07"/>
                    <measurement group_id="O2" value=".16" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Endpoint</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".17" spread=".09"/>
                    <measurement group_id="O2" value=".18" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".16" spread=".09"/>
                    <measurement group_id="O2" value=".18" spread=".11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".16" spread=".12"/>
                    <measurement group_id="O2" value=".16" spread=".12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were not formally collected. However, any informal report via a participant was recorded from the initial baseline session to the two follow-up assessments. All-cause mortality was not assessed.</time_frame>
      <desc>Because the study involved staff from both Boston University and Massachusetts General Hospital, participants signed a consent form for each institution. Subsequently, all serious adverse events (SAEs) were reported to the IRBs of both institutions. All SAEs were reported within 24 hours of discovery. SAE reports were collected in a non-systematic matter and all were judged by the investigators to be unrelated to the study procedures.
Adverse events (AEs) were not assessed in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive Behavioral Therapy
Cognitive Behavioral Therapy: 12 weekly sessions and 3 booster sessions of cognitive behavioral therapy</description>
        </group>
        <group group_id="E2">
          <title>Individual Drug Counseling</title>
          <description>Individual Drug Counseling
Individual Counseling: 12 weekly sessions and 3 booster sessions of individual counseling</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Clot</sub_title>
                <description>Hospitalization for five days due to formation of a blood clot around the central artery, where a central IV had previously been placed. Patient was treated by hospital staff with prescribed self-injection and a blood thinner.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>High Glucose Levels</sub_title>
                <description>Hospitalization due to extremely high glucose levels resulting from diabetes.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Foot Ulcer</sub_title>
                <description>A participant was hospitalized for a chronic foot ulcer problem. Hospitalization lasted for two weeks, but the participant still completed his study visits. The medical event was judged to be in no way related to the study procedures.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hospitalization for Chronic Health Concerns</sub_title>
                <description>Hospitalization for four days. Participant had chronic health concerns and completed the active treatment phase of the study and had been discharged from the clinic before hospitalization. This SAE was unrelated to study procedures.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>Hospitalization for two to three days for an infection and unspecified chronic health problems. Participant resumed and completed study procedures upon discharge from the hospital. This event was unrelated to study procedures.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hospitalization for Chronic Health Concerns</sub_title>
                <description>Hospitalization for four days. Participant had chronic health concerns and completed the active treatment phase of the study and had been discharged from the clinic before hospitalization.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Sprain</sub_title>
                <description>Participant was partially hospitalized for a sprained left ankle. Hospitalization was required due to patient's perceived medical risk. This event was judged to be unrelated to study procedures.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hairline fracture</sub_title>
                <description>Participant was admitted to the ER secondary to bruised ribs and hairline fracture secondary to falling from a chair.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Stab Wound</sub_title>
                <description>Participant was hospitalized for five days for various medical problems related to a stab wound, including several blood transfusions. Participant resumed dosing at the clinic and resumed study procedures.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Wound Treatment</sub_title>
                <description>Participant was hospitalized overnight for 3 days. Participant was beaten over the head and received treatment for his wounds at this hospital. Participant resumed dosing at the clinic and continued study procedures.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Participant hospitalized for dehydration. Following discharged, participant resumed dosing at the clinic and continued with study procedures.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Oversedation</sub_title>
                <description>Participant was hospitalized secondary to &quot;oversedation.&quot; Patient subsequently sought out inpatient detox, complaining of overprescription of a benzodiazepine medication and acute psychiatric symptoms.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Detoxification</sub_title>
                <description>Participant reported being admitted to a residential substance abuse treatment facility for detoxification. The patient remained at the facility for 30 days. The admission to the facility occurred prior to randomization to treatment condition.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>Inpatient psychiatry hospitalization for six days due to symptoms of depression. Patient denied suicidal ideation, and stated that hospitalization was required for emergency medication management.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Detoxification</sub_title>
                <description>Participant voluntarily entered an inpatient unit for five days for the detoxification of benzodiazepines. Participant resumed and completed study procedures upon discharge from the hospital. This event was unrelated to study procedures.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Detoxification</sub_title>
                <description>Participant was hospitalized for detoxification and mental health problems. This participant was subsequently discharged from the methadone clinic and did not complete study procedures. This event was unrelated to study procedures.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <description>Participant reported losing housing, and reported suicidal ideation to a (non-study) counselor to obtain emergency housing. Participant was at this unit for several days, yet came to the methadone clinic as part of scheduled study involvement.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <description>Participant reported serious psychological distress to study staff. After assessing suicidal ideation, it was decided that this situation warranted intervention.The participant was then independently assessed and hospitalization by clinic staff.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Detoxification</sub_title>
                <description>Participant voluntarily entered an inpatient detoxification unit for the detoxification of heroin and benzodiazepines. Upon discharge from the detoxification facility, the participant resumed regular study involvement and completed study procedures.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Detoxification</sub_title>
                <description>Participant voluntarily entered an inpatient unit for 5 days for the detoxification of benzodiazepines. Upon discharge from the detoxification facility, the participant resumed regular dosing at the methadone clinic and resumed study procedures.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <description>The investigators were notified that a participant was hospitalized again for suicidal ideation. The clinic staff independently assessed the patient and deemed that hospitalization was necessary.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Detoxification</sub_title>
                <description>Participant voluntarily entered an inpatient detoxification unit. Upon discharge from the detoxification facility, the participant resumed regular study involvement.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney infection</sub_title>
                <description>Participant was hospitalized due to a kidney infection secondary to an untreated urinary tract infection. This event was judged to be unrelated to study procedures.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Groin Injury</sub_title>
                <description>Participant was hospitalized due to problematic functioning in the patient's groin area.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Kidney Stone</sub_title>
                <description>Participant was hospitalized for several days for a kidney stone. Participant was released and resumed dosing at the clinic and resumed study procedures.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Hospitalization due to pneumonia resulting from chronic condition that compromises immune functioning.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Participant was hospitalized for four days due to pneumonia, inflamed intestines, and high blood pressure (as per patient report). Investigators learned about the SAE after patient has been discharged.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Respiratory Problems</sub_title>
                <description>Hospitalization due to low blood pressure and respiratory problems.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Hospitalization for seven days due to a bout of pneumonia.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Participant was hospitalized for 7 days for pneumonia. This participant has a history of chronic health problems, which worsened to the point that IV antibiotics were needed. Participant resumed dosing at the clinic and resumed study procedures.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael W. Otto, Ph.D.</name_or_title>
      <organization>Boston University Charles River Campus</organization>
      <phone>(617)353-9610</phone>
      <email>mwotto@bu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

